Fig. 2From: New therapeutic strategies to treat human cancers expressing mutant p53 proteinsMutant p53 is targeted by small molecules. PRIMA-1, MIRA-1, diverse kind of peptides and small compounds bind to mutantp53 and restore wild-type p53 tumor suppressor abilities. Moreover, they block mutantp53-induced inhibition of TAp73 restoring its transactivation activityBack to article page